Medical Chemical Defense (Op Sys Dev)
Abstract
This project provides for the upgrade and modernization of fielded medical nerve agent treatment system that contribute to the layered medical defenses against chemical warfare agent threats facing U.S. Forces in the field. The effort included in this project are: (1) Alternative Autoinjector Manufacturer Capability (AUTOINJ) (2) Improved Nerve Agent Treatment System (INATS), and (3) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) The AUTOINJ program provides for FDA approved alternative source(s) for autoinjectors that deliver DoD nerve agent antidote and treatment capabilities to the warfighter; thereby mitigating capability fielding and operational readiness risks. This program augments legacy autoinjectors, ATNAA, 2-PAM, and Convulsant Antidote for Nerve Agents (CANA) by providing alternative commercial sources which include Dual Drug Delivery Device (D4), the Atropine Auto-Injector, and an anti-convulsant autoinjector. This program also provides enduring regulatory support for fielded nerve agent antidote treatment systems sponsored by Army Office of the Surgeon General (OTSG). AUTOINJ (MC7) will transition to Modernization Medical (MOD MED) MB7 starting in FY22. The INATS - Soman Nerve Agent Pre-Treatment Pyridostigmine (SNAPP) program is a modernization effort for pyridostigmine bromide (PB) tablet requirements from the joint service users for the Food and Drug Administration (FDA) approved SNAPP product. Funding ends in FY20. Effort will continue in FY21 as INATS CA. The INATS CA program provides a Centrally Acting anticholinergic agent to increase survivability and decrease morbidity after exposure to toxic nerve agent threats. Scopolamine was selected for development after an extensive analysis of alternatives and review of data by the Science and Technology community. Added to the currently fielded system, the INATS-CA program will improve overall medical outcomes and will be utilized as both a vial for use at definitive care and a stand-alone auto-injector for use in the field. In FY22 INATS CA continues studies on the FDA-approved Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP), a medical pre-treatment against nerve agent poisoning to upgrade its joint service utility and ensure its continued safety and efficacy.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2022
- Source ID
- MC7_0607384BP_7_0400_PB_2022
Related Documents
- Root: CHEMICAL/BIOLOGICAL DEFENSE (OP SYS DEV)
- Child Accomplishment: 1) Alternative Autoinjector Manufacturer Capability (AUTOINJ)
- Child Accomplishment: 2) INATS
- Child Accomplishment: 3) INATS - CA
- Child Cost Item: 01436117ebbe39df57740f7c2ab14ad6
- Child Cost Item: 49bf955d366cf7d014ee9f9c540ece96
- Child Cost Item: be14571707c84d8aa6c7732ce7551648
- Child Cost Item: 5ecb6ec0a74ea78cf5a90e139bc625fa
- Child Cost Item: 3db278417f98ec9a1d8059016a8b9df1
- Child Cost Item: 48d5ab869923c6220cdcb8fd1b568516
- Child Cost Item: cc272b5874261b439bc828416f2e66cc
- Child Cost Item: fd74bd4f45cf9c01395d391b93ec6200